Skip to main content Skip to search Skip to main navigation

ICH: Parallel Guidances Q2(R2)/Q14 on Analytical Procedures adopted

The Assembly of the International Council for Harmonisation (ICH) adopted the revised Q2(R2) Guideline on the Validation of Analytical Procedures and the new Q14 Guideline on Analytical Procedure Development. They jointly describe the development and validation activities that should be applied during the life cycle of an analytical procedure to assess the quality of medicinal substances and products.

Both documents reached Step 4 of the ICH process, are now harmonised, and represent the current state of science and technology. This was announced following the ICH's 31 October 2023 meeting in Prague. Draft documents for the guidelines were first presented in March 2022 (we reported).

  • The scope of the revision of ICH Q2(R1) includes validation principles that cover the analytical use of spectroscopic or spectrometry data (e.g., NIR, Raman, NMR, or MS) some of which often require multivariate statistical analyses.
  • The new guideline Q14 provides principles relating to the description of the analytical procedure development process. It is intended to improve regulatory communication between industry and regulators and facilitate more efficient, sound scientific, and risk-based approval as well as post-approval change management of analytical procedures.

An Expert Working Group (EWG) will now transition to an Implementation Working Group (IWG) to develop training materials for both guidelines. Furthermore, the guidelines will be implemented and published shortly on the ICH website. This step is currently pending. The Q2(R2) and Q14 guidelines are intended to complement the ICH guidelines Q8 to Q12, as well as the current ICH guideline Q13 for continuous manufacturing.


Source:

ICH: Press Release on ICH Assembly Meeting, Prague, Oct 2023

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Annex 22: EMA Workshop on AI in GMP

Annex 22: EMA Workshop on AI in GMP

The European Medicines Agency (EMA) will hold a two-day multistakeholder workshop on 30 June and 1 July 2026 to gather expert input for the development of Annex 22 of the EU GMP Guide on the use of artificial intelligence (AI) in medicines manufacturing.
Read more
FDA: Pilot Program for One-Day Inspectional Assessments

FDA: Pilot Program for One-Day Inspectional Assessments

Since April 2026, the U.S. FDA has been piloting “One-Day Inspectional Assessments” as a complement to standard FDA inspections.
Read more
EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

EU: Commission Implementing Regulation on QM and Conformity Assessment Activities of Notified Bodies

Commission Implementing Regulation (EU) 2026/977 of 4 May 2026 further specifies requirements for notified bodies under the MDR and IVDR frameworks and aims to promote a more harmonised implementation across the European Union.
Read more
The ABC of User Requirements Specification (URS)

The ABC of User Requirements Specification (URS)

In the URS, the future user defines what the system should be capable of, but also what it is limited to. In addition to the (testable!) technical requirements, regulatory require-ments should also be taken into account.
Read more
What is the Importance of Data Integrity?

What is the Importance of Data Integrity?

Here's the answer:
Read more
EDQM: Updated Guideline on CEP Revisions and Renewals

EDQM: Updated Guideline on CEP Revisions and Renewals

The European Directorate for the Quality of Medicines & HealthCare has published a revised version of its guideline on the revision and renewal of Certificates of Suitability (CEPs) (PA/PH/CEP (04) 02), aligning it with recent EU legislation on variation procedures.
Read more
Previous
Next